PeptideStack
5.2kquestions
20kanswers
220users

How do I trace an MKM lot number back to a synthesis date?

Asked 3 Jan 2025Modified 15 months agoViewed 51k times
36

I have both a purity figure and a content figure, which is why the discrepancy is visible.

I want a method I can write down and repeat, not a rule of thumb.

I would rather over-engineer this than discover a problem later, within reason.

Concretely, what should I do, and how would I know afterwards whether I did it right?

batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

910 questions
coa
coa

Certificates of analysis: what fields a useful one carries, how to tell a real analytical report from a marketing document, batch and lot…

771 questions
vendor-vetting
vendor-vetting

Evaluating a supplier on evidence rather than reputation: testing history across batches, whether certificates are batch-specific, how failures…

454 questions
shareeditfollowflag
RM
askedrosa_mendieta8k163 Jan 2025

5 Answers

Accepted answer first, then by votes
79

Accepted answer

Mechanically, if a lot has visibly segregated — some vials showing different appearance — then sampling the top and bottom of the shipment is worth doing.

Published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.

Reconciling gross mass to label claim

ComponentTypical shareCounted in purity?Counted in content?
Target peptide88–94 %Yes, as main peakYes
Related impurities1–3 %Yes, as other peaksNo
Counter-ion (TFA or acetate)2–8 %NoNo
Residual water2–6 %NoNo
Bulking agent, if present0–40 %NoNo

Stated carefully, if you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.

Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.

The caveat is that sampling is a trade-off between cost and confidence, and neither test nor assumption is cost-free.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

shareimprove this answerflag
AL
answered · accepteda_lindgren58k24825 Feb 2025
7The distinction between purity and content cannot be repeated often enough here. – tobias_maartens 4 months ago
add a comment
Sponsored

Janoshik Analytical - Independent Third-Party Testing

HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.

Submit a sample
Sponsored — paired listing

GL Biochem (Shanghai) Ltd. - Direct Synthesis

Founded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.

Visit GL Biochem
94

The practical consequence is that spot-testing one vial from a new supplier is better than assuming they are all the same.

The statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.

Put another way, if the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.

Assume segregation is possible, and design your sampling to catch it if it exists.

edited 30 Mar 2025 by j_wierzbicki — added the placebo-arm figures

shareimprove this answerflag
JW
answeredj_wierzbicki69k14819 Mar 2025
38

Worth being precise here: two vials tested from a lot of ten is very different from two vials tested from a lot of ten thousand, and most certificates do not state the lot size.

For a quantitative result like content, the acceptable range determines how many vials you need to test to establish the lot complies.

If the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.

Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.

One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.

If testing multiple vials, state how many you tested and why you chose those vials.

shareimprove this answerflag
NN
answerednine_point_nine60k14814 Feb 2025
6Do you have the chromatogram for this, or just the summary figure? – Dr_Colm_Fitzhenry 8 months ago
5Adding for future readers: the certificate should carry the lot number, not just a batch code. – bac_or_bust 7 months ago
add a comment
30

Sampling plans exist precisely because testing everything is expensive, and they define the statistical relationship between sample size and lot-wide inference.

Stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.

Worth noting that thermal excursions during shipping affect different vials differently, so the lot may not be homogeneous even if it left the factory that way.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

shareimprove this answerflag
AL
answereda_lindgren58k2483 May 2025
Thank you — this is the answer I was looking for. – bac_or_bust 4 months ago
add a comment
1

Specifically, the failure mode here is publishing a result that applies to the tested vial alone while implying it applies to the entire lot.

Testing a vial that has been open in the lab for three months is testing aged material, not the fresh lot, and the result should be explicitly noted as a retest.

Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.

shareimprove this answerflag
KA
answeredkwn_analytical147k3588 Mar 2025
3The system-suitability data is the part that tells you whether to believe the rest. – nkem_obiora 8 months ago
2Does this hold for a longer chain length, where the deletion sequences accumulate? – marta_okonkwo 7 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.